Gut peptides including GLP-1, GIP, and others form a gut-brain axis that regulates glucose metabolism, with incretin-based drugs (GLP-1 agonists, DPP-4 inhibitors) directly exploiting this physiology for diabetes treatment.
Key findingThe gut-brain glucose regulatory axis operates through incretin peptides (GLP-1, GIP), neural signals, and other gut hormones to control glucose metab
What the researchers found
The gut-brain glucose regulatory axis operates through incretin peptides (GLP-1, GIP), neural signals, and other gut hormones to control glucose metabolism — pharmacological exploitation has produced GLP-1 agonists and DPP-4 inhibitors as major diabetes drug classes.
Why it matters
Relevant for glp-1, diabetes, weight-loss.
How the study worked
review study on glp-1, diabetes.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Gut-brain axis: regulation of glucose metabolism.
Journal of neuroendocrinology, 18(12), 883-94
Citation
Heijboer, A C; Pijl, H; Van den Hoek, A M; Havekes, L M; Romijn, J A; Corssmit, E P M. (2006). Gut-brain axis: regulation of glucose metabolism.. Journal of neuroendocrinology, 18(12), 883-94.